Impact of the Use of Allogeneic Hematopoietic Stem Cell Transplantation in Reunion Island Patients: Quality of Life, Determinants of Choices and Financial Repercussions
Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE LA RÉUNION · Apr 7, 2022
Trial Information
Current as of July 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how living far away from mainland France affects patients in Reunion Island who need a special treatment called allogeneic hematopoietic stem cell transplantation (alloSCT). This treatment is often necessary for people with certain blood cancers, like leukemia and lymphoma. The study will explore three main areas: the quality of life of patients and their caregivers, the choices they make regarding the treatment, and the financial impacts on both the patients and the healthcare system.
To participate in this trial, individuals must be over 18 years old, diagnosed with a blood cancer, and planning to get their stem cell transplant in mainland France. They should also be able to fill out a questionnaire about their experiences. The trial is not yet recruiting participants, but it aims to gather important information that could help improve the care and support for patients living in Reunion Island. If you or someone you know is considering this treatment, this study could provide valuable insights into the overall experience and challenges faced by patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients diagnosed with hematological malignancy (myeloid acute leukemia, lymphoid acute leukemia, non-hodgkin lymphoma, Hodgkin disease, or myelodysplasic syndrome
- • candidate to an allogeneic hematopoietic stem cell transplantation in mainland France ;
- • Residing in Reunion Island
- • Age \>18 year old;
- • who accept or not allogeneic hematopoietic
- • Able to complete a questionnaire
- Exclusion Criteria:
- • Opposition to participation and collection of their data
- • Person deprived of liberty by judicial or administrative decision, and person subject to legal protection (guardianship or curators)
About Centre Hospitalier Universitaire De La Réunion
The Centre Hospitalier Universitaire de la Réunion (CHU Réunion) is a leading academic medical center located on the island of Réunion. As a prominent clinical trial sponsor, CHU Réunion is dedicated to advancing medical research and improving patient care through innovative therapeutic studies and collaborations. With a focus on multidisciplinary approaches, the institution leverages its expertise in various medical fields to address pressing health challenges, enhance clinical practices, and promote evidence-based medicine. CHU Réunion is committed to ensuring patient safety and ethical standards in all research endeavors, contributing to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Saint Pierre, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials